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Background: Comparative effectiveness research (CER) documents important differences in antidepressants in
terms of efficacy, safety, cost, and burden to the patient. Decision aids can adapt this evidence to help patients
participate in making informed choices. In turn, antidepressant therapy will more likely reflect patients’ values and
context, leading to improved adherence and mood outcomes.
Methods/Design: The objective of this study is to develop the Depression Medication Choice decision aid for use
during primary care encounters, and to test its efficacy by conducting a clustered practical randomized trial
comparing the decision aid to usual depression care in primary care practices.
We will use a novel practice-based, patient-centered approach based on participatory action research that involves
a multidisciplinary team of designers, investigators, clinicians, patient representatives, and other stakeholders for the
development of the decision aid. We will then conduct a clustered practical randomized trial enrolling clinicians
and their patients (n = 300) with moderate to severe depression from rural, suburban and inner city primary care
practices (n = 10). The intervention will consist of the use of the depression medication choice decision aid during
the clinical encounter. This trial will generate preliminary evidence of the relative impact of the decision aid on
patient involvement in decision making, decision making quality, patient knowledge, and 6-month measures of
medication adherence and mental health compared to usual depression care.
Discussion: Upon completion of the proposed research, we will have developed and evaluated the efficacy of the
decision aid depression medication choice as a novel translational tool for CER in depression treatment, engaged
patients with depression in their care, and refined the process by which we conduct practice-based trials with
limited research footprint.
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Depression is one of the most common chronic illnesses in
the USA, and decreases the quality and duration of life of
over 16 million Americans. Impacting not only individuals,
depression causes suffering to family and friends, losses in
productivity, and other costs to society [1]. Despite a life-
time prevalence of 17%, depression is often undetected and
suboptimally managed, particularly in primary care where
80% of patients with depression receive care and 75% of
antidepressant prescriptions are provided [2,3]. Unfortu-
nately, adherence to antidepressants is low, with contem-
porary cohorts citing 6-month rates in the range of 13% to
60% [4,5], and many patients who are initially adherent dis-
continue prematurely [6]. Primary nonadherence and pre-
mature discontinuation are associated with 77% increased
risk of relapse or recurrence, and adverse effects on disabil-
ity and healthcare utilization [7-9]. Thus, even when pa-
tients with depression are detected and diagnosed properly,
over 60% will have adequate fidelity to treatment and many
will suffer protracted clinical course with great cost implica-
tions in terms of dollars and human suffering.
Lifestyle changes, self-care practices, evidence-based
psychotherapy and pharmacotherapy can improve de-
pression outcomes, lower healthcare costs and improve
the quality of life. When it comes to pharmacotherapy,
depression care often demands primary care clinicians’
and patients’ use of therapy and medication regimens of
different efficacy, safety, cost, and burden to the patient;
findings vary according to depression severity and recur-
rence, underscored by the emerging literature on their
comparative effectiveness [10,11]. Moreover, the transla-
tion of the evidence from comparative effectiveness re-
search (CER) remains limited [12].
Patient decision aids can facilitate the translation of CER
into practice. When systematically summarized, CER can
inform the content of decision aids, including the range
and likelihood of desirable and undesirable outcomes
across the different options. These tools can be designed
to facilitate patient involvement in making decisions even
among patients and clinicians with limited experience in
shared decision making [13-15]. We have previously
shown that decision aids that provide easily accessible in-
formation about treatment options and their outcomes for
other chronic conditions facilitated knowledge transfer
and greater patient involvement in usual primary care set-
tings, and showed promise in improving adherence to
therapy [14,16,17]. To our knowledge, there is no research
evaluating the use of patient decision aids within the clin-
ical encounter, to facilitate the participation of patients
with moderate to severe depression in choosing antide-
pressants in practice.
Consequently, to determine the ability of a decision aid
to effectively translate CER about antidepressants into prac-
tice, we will first develop a decision aid, the DepressionMedication Choice, for use during primary care encounters
that would meet the needs of key stakeholders (patients
and clinicians, health plans, and payers), while enabling
shared decision making as a way of translating antidepres-
sant CER into practice. We will then enroll primary care
practices and randomly assign these to either usual depres-
sion care or to care involving use of the depression medica-
tion choice decision aid. This trial, still underway, will
generate preliminary evidence of the relative impact of the
decision aid on patient involvement in decision making, de-
cision making quality, patient knowledge, and 6-month
measures of medication adherence and mental health com-
pared to usual depression care.
Methods/Design
Development of the Depression Medication Choice
decision aid
We will use a novel practice-based, patient-centered ap-
proach for decision aid development based on design/par-
ticipatory action research, developed and validated by the
Knowledge and Evaluation Research Unit at Mayo Clinic
(Rochester, MN, USA), and executed by a multidisciplin-
ary team comprised of designers, patients, primary care
and psychiatry clinicians, and decision making and health
literacy scientists (Figure 1) [13,14,17].
This approach includes three main steps: 1. synthesis of
clinical evidence regarding the risks and benefits of each
option, and its approval by stakeholders; 2. observations of
real-time clinical encounters involving clinicians and their
patients with depression facing the decision to use antide-
pressants; and 3. prototyping of the decision aid through a
series of iterations and field testing in the same context as
the initial observations.
Synthesis of evidence
For the purpose of the development of the depression
medication choice decision aid, we will synthesize the evi-
dence regarding the risks and benefits of antidepressants
based on the Agency for Healthcare Research and Quality
(AHRQ) effective healthcare systematic review report on
the comparative effectiveness of second generation antide-
pressants (07-EHC-007) [18]. We will then convene psy-
chiatrists, primary care clinicians, patients and health plan
representatives to meetings in which they will review the
summary, and agree on its results and associated credibil-
ity and applicability.
Observation of encounters
Members of the research team led by a designer will ob-
serve approximately 10 to 15 usual clinical encounters,
typically 3 to 5 without aids, and 3 to 5 with each iteration
of the decision aid prototype. Using a predefined observa-
tion grid we developed and used in previous studies, we
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Figure 1 Development of a decision aid.
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behaviors and attitudes.Prototyping and field testing
The construction of the Depression Medication Choice
will be based on the summary of evidence and clinical ob-
servations, guided by the International Patient Decision
Aid Standards (IPDAS) [19], which provides recommen-
dations and standards for the development of decision
aids. The initial prototype of the decision aid will result
from discussions with members of the study team, clini-
cians, and patients from our patient advisory groups. They
will be asked to comment on the content, format and ease
of use of the prototype, on how the prototype aid captures
current knowledge and addresses their concerns about an-
tidepressants, and on to what extent the prototype helps
bring to light patient context, values and preferences for
decision making. Once developed, we will pilot this initial
prototype in 3 to 5 clinical encounters, looking for pat-
terns of the conversations, and documenting the issues,
problems and challenges. When feasible, we will conduct
a brief structured interview with the patient and the clin-
ician after the encounter. The study team will then evalu-
ate the quality of the conversations and the ability of the
prototype to facilitate the decision making process. This
process will be repeated with subsequent prototypes until
the research team and stakeholders reach a consensus that
the prototype is successful in involving patients in decision
making (in our prior work it has taken up to seven itera-
tions). This process should result in a discrete and highly
intuitive decision aid, requiring minimal training to use,
and designed to meet the needs of patients and their pri-
mary care clinicians working in fast-paced care settings.Evaluation of the impact of the Depression Medication
Choice decision aid
Study design and setting
We will conduct a clustered, practice-based, randomized
trial of the Depression Medication Choice decision aid in
ten rural, suburban and inner city primary care practices in
the Midwest USA. The Mayo Clinic Institutional Review
Board (IRB) has approved the study procedures described
herein. We also obtained ethical approval from Hennepin
County Medical Center Human Subjects Research Com-
mittee for the three participating practices not covered
under the Mayo Clinic IRB. The trial design and protocol
are registered in ClinicalTrials.gov (NCT01502891).
Study participants
Primary care practices were invited to participate in the
study based on key criteria for a successful collaboration
identified from past similar trials: sufficient number of cli-
nicians interested in participating; an easily identifiable
clinical champion; a large enough patient population meet-
ing our inclusion criteria; and an on-site, or willingness to
have an on-site, study coordinator. Practices that had con-
current research studies involving antidepressants were
automatically excluded from participating in the study.
Primary care clinicians (physicians, nurse practitioners,
physician assistants) from participating practices will be
eligible for the study if they provide care to patients suffer-
ing from depression. Eligible clinicians will be invited to
participate in the study through an initial meeting held by
the investigators at the practice or individually by the on-
site study coordinator.
Adult patients will be eligible for the study if they have a
diagnosis of depression as judged by the clinician, a score
on the Patient Health Questionnaire (PHQ-9) ≥10 [20],
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do not have bipolar disorder (as judged by the clinician),
and have no major barrier (language, sensorial, cognitive)
to providing written informed consent.
Eligible patients will be identified in advance from the
appointment schedules of clinicians. All eligible patients
who present to the practice for a depression visit during
the study will be invited by an on-site study coordinator
to participate in the study.
Allocation procedures
We will randomly allocate practices to the intervention or
usual care arm. We will pair practices by size (the number
of clinicians seeing adult patients with depression) and by
whether they have implemented the DIAMOND (Depres-
sion Improvement Across Minnesota, Offering a New Dir-
ection) program, a practice redesign initiative to improve
depression care through the use of care coordinators [21].
Within each pair, we will randomize practices to either: 1.
the use of Depression Medication Choice within the clin-
ical encounter; or 2. usual care. A study statistician will
perform the randomization centrally after the practices
have been enrolled and ensure concealment of allocation.
Practices, clinicians and investigators will not be
masked to allocation. However, patients will remain un-
aware of the study’s main hypotheses. To prevent loss to
follow-up and support the intention-to-treat principle,
we will centrally follow patients, and ensure that patient
surveys and pharmacy follow-ups are complete.
Intervention
The intervention will consist of the use of the Depres-
sion Medication Choice decision aid by patients and
their primary care clinician during the clinical encounter.
Training of clinicians will be provided prior to enrollment
of their patients and will include a demonstration showing
how to use the decision aid with patients. The focal points
of the demonstration will be: 1. the decision aid serves as
a guide for conversation rather than a script; 2. clinicians
have flexibility in the manner in which they use the deci-
sion aid, including how and when they use it during the
visit; and 3. clinicians may elect not to use the tool with
certain enrolled patients, per their own judgment. Brief
video clips and a storyboard to demonstrate the basic use
of the decision aid will be available for clinicians to review
at their convenience. A study team member will remain
available to undertake one-to-one demonstrations after
the initial group demonstration, as needed.
Usual care
For patients in the usual care arm, clinicians will manage
the discussion about medication regimen as usual, with-
out using the decision aid.Data collection and analysis
We will collect patients’ data through: 1. self-reported
questionnaires administered before and after the clinical
encounter with their clinician, and at 3 and 6 months
post-encounter; and pharmacy data 2. information about
depression-related care included in medical records. Par-
ticipating clinicians will be given brief questionnaires to
complete once before and then immediately following
each clinical encounter with a participating patient. In
addition, we will videotape each clinical encounter where
consent to do so has been provided by both the patient and
clinician. Patient, clinician and practice socio-demographic
information will be collected through questionnaires, and
administrative or patient medical records.Outcomes measures
The RE-AIM framework, developed to address how an
intervention is implemented in a real-world setting, will
guide this portion of the study and includes the follow-
ing dimensions: Reach (how broadly is this intervention
used within the practices), Effectiveness (what is the im-
pact of the intervention on outcomes), Adoption (can
this be adopted by new groups with ease and minimal
modifications), Implementation (what are the special is-
sues and barriers in implementation), and Maintenance
(can the intervention be maintained and will the impact
continue) [22,23].
To assess the Reach of the decision aids, we will use a
tracking log to record patients who are enrolled as well as
those who declined the invitation to participate, and their
respective characteristics. This will allow us to measure
participation and representativeness.
To assess the Effectiveness of the decision aids, we will
measure patient decisional conflict as the primary out-
come, and decision making quality and processes (that is
knowledge, satisfaction, preference in decision making
style, patient involvement in decision making), depression
outcomes, and medication adherence as secondary out-
comes in the following ways:
1 Decisional conflict. Patients will complete the
decisional conflict scale (DCS) immediately after the
clinical encounter, the most commonly used
outcome measure in decision aid trials [24,25].
Psychometric properties include good internal
consistency, test-retest reliability, and effect sizes for
responsiveness to change ranging from 0.4 to 1.2.
Clinicians will also complete a similar scale
immediately after the clinical encounter [26].
2 Knowledge. Patients will complete a questionnaire
addressing general and specific knowledge about
depression care contained in the decision aids. This
questionnaire will be developed according to prior
LeBlanc et al. Trials 2013, 14:127 Page 5 of 8
http://www.trialsjournal.com/content/14/1/127recommendations and will be completed after the
encounter, and at 3 and 6 months post-encounter.
3 Satisfaction. Patients and clinicians will be asked
questions regarding the acceptability and satisfaction
regarding the way information was shared during
the encounter.
4 Preference. Patients will identify their preference in
decision making style prior to and after the encounter
[27]. Clinicians will also complete the same
questionnaire at enrollment in the study and following
each encounter with a participating patient.
5 Patient involvement in decision making. We will use
the Observing PatienT Involvement in shared
decisiON making (OPTION) scale to assess the extent
to which clinicians seek to engage patients in decision
making [28]. Our group has extended the use of this
third-observer tool using video recordings of the
encounters, with excellent inter-rater reliability
(intraclass correlation coefficient >0.7) [14,16,17,29].
6 Depression outcome. Patients will complete the nine
items of the PHQ-9 [20], as a measure of the
severity of depression symptoms, before their
encounter, and at 3 and 6 months post-encounter.
7 Medication adherence. Patients’ measure of
adherence and persistence to their depression
medication will be derived from patient self-report
and pharmacy records. We have been able to obtain
complete pharmacy records for all of our
participants in previous trials [14,16,17].
When mentioned the Adoption of the decision aids,
we will estimate the proportion of practices or
clinicians who adopt the intervention. Using
clinician surveys and medical record review, we will
compare the adoption rates across the intervention
practices. We will select a random sample of
participating patients’ medical records from each
site to determine the extent to which the use of the
decision aid is discernible in the records, and the
extent of use and success when mentioned.
To assess the Implementation of the decision aid, we
will seek to determine the extent to which the interven-
tion (that is, use of the depression medication choice de-
cision aid) is implemented as intended. Using the video
recordings of the clinical encounters, we will assess the
fidelity with which the decision aids are delivered and
used as intended during these clinical encounters. The
fidelity checklist is specific to the decision aid and set-
ting, and will be developed based on previous checklists
for other decision aids.
We will not be able to assess the Maintenance of the use
of decision aid in practices as this requires a time period
that is outside of the scope of the funding of the
current study.Socio-demographic and other patient characteristics
At entry in the study, patient characteristics collected will
include age, gender, marital status, education, income, sub-
jective health literacy [30,31] and subjective numeracy [32].
We will collect the following clinician characteristics: gen-
der, birth year, position, practice specialty and number of
years in practice. Practice-level characteristics will include
distribution of patient ethnicity, race, payment method,
population of community, location of clinic (urban, subur-
ban, rural), distribution of full-time equivalent across staff
(clinicians, nursing staff, educators), average number of
visits per week and average length of appointments.
Sample size
The Statin Choice randomized trial evaluated the decision
quality by comparing the decision aid to usual care, and
reported a 9.8 point difference in decision quality with the
standard deviation (SD) of 16.9 and 14.1 for the usual care
and decision aid groups, respectively [16]. Thus, to deter-
mine the statistical power of the current trial, we made the
following assumptions: 1. variances will be as reported in
the statin choice study; 2. the trial should detect a differ-
ence of 9.8 points or greater in decisional conflict between
two groups at a significance level of 0.05, with a two-sided
t-test; 3. a modest correlation of outcomes within practices
represented by an intracluster correlation coefficient (ICC)
(between cluster variance/total variance) of 0.05; and 4. a
10% attrition rate. We estimated the power using a stand-
ard calculation for a t-test, adjusted for clustering by a
variance inflation factor (VIF) (1 + (n − 1) x ICC), where n
is the number of patients per practice [33]. Under these as-
sumptions, we estimated that we will have 90% power to
detect at least a 9.8 difference in the DCS if we are able to
recruit 30 patients per clinic for a total recruitment target
of 300 patients. Assuming a similar ICC and attrition
rate for other outcomes, this sample size will have 99%
power to detect 1 SD difference in any continuous meas-
ure (for example approximately a 2-point difference in a
10-question knowledge scale), and 80% power to detect
a 30% difference in 6-month adherence rates assuming a
control adherence rate of 50%. Actual power is likely to be
greater because we will adjust for baseline values and char-
acteristics, and because of our conservative assumptions.
Analysis
Rather than assume that patient outcomes are independent
of the clinician and practice, we will use techniques appro-
priate for clustered observations [33,34]. For unadjusted
comparisons, we will use cluster-adjusted t-tests and
chi-square tests, and for all adjusted analyses we will use
hierarchical generalized linear models (HGLMs) [35,].
These statistical methods address the ‘unit of analysis’ issue
through terms for each level of grouping or clustering, and
have a number of features important to this study.
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ing of patients within clinicians and practices, and allow us
to deal with repeated observations of patients. Three types
of outcomes will be compared between randomization
groups, as classified by measurement period and unit of
observation: 1. patient-level after the index visit; 2. patient-
level after 6 months; and 3. clinician-level outcomes at end
of the study period. All patient and clinician outcomes will
be analyzed as randomized in adherence to the intention-
to-treat principle. Patient characteristics will be compared
between randomization groups, and all outcomes adjusted
for any that are not balanced between groups.
We will measure the following outcomes at the patient-
level after the index visit: 1. Decision to initiate antidepres-
sants. This will allow us to estimate the differences in
prescription of medication for the decision aid group com-
pared to the control group. As a secondary analysis, we
will conduct subgroup analyses by health literacy level to
test for an interaction. We will use this test to determine
whether the difference in uptake of depression medica-
tions in the decision aid and control arms differs for the
low versus high health literacy groups; 2. Decisional con-
flict and decisional quality and processes. Through these
analyses, we will evaluate the effect of decision aids on de-
cisional quality, patient satisfaction with the encounter,
and patient knowledge related to the decision.
We will evaluate the following outcomes at the patient-
level using 3- and 6-month data: 1. Antidepressant medi-
cation persistence and adherence based on decision at the
index visit. Medication persistence will be measured as
continuation of depression medications at 6 months for
patients who leave the index visit with prescriptions for
antidepressants; this includes their first medication and
changes in the prescriptions that occur in the 6 months
following the index visit. Medication adherence will be
measured using fill dates from the pharmacies, measured
using the percentage of days covered approach; 2. Depres-
sion outcomes. Depression treatment outcomes will be
measured at baseline and at 3 and 6 months using the
PHQ-9 [20]. This is the measure used by practice-based
interventions in primary care, such as the DIAMOND ini-
tiative, there are practice pathways to collect this informa-
tion, its score is linked to clinical action and it is familiar
to primary care clinicians [36].
Finally, we will evaluate the clinician-level outcomes also
using random effect models. However, for these analyses
we will only cluster within clinic and account for the re-
peated measures for satisfaction and visit length, while
controlling clinician and practice characteristics.
Discussion
This study seeks to develop a decision aid for depression
medication, to be used by clinicians and patients in the
clinical encounter, and to evaluate its impact in a clusteredrandomized trial in diverse primary care practices. Our
use of this tool is consistent with a strong theoretical and
empirical basis supporting the use of decision aids, our
preliminary work supporting the feasibility and efficacy of
decision aids in other treatment decisions with patients
with chronic conditions, and the evolving international,
national and local policy support for patient involvement
in decision making [14,16,17,37].
In our view, this protocol offers several innovative and
important aspects. We propose the development and use of
a novel translational tool in depression care, the Depression
Medication Choice decision aid, to help clinicians and
patients engage in meaningful conversations regarding
the use of antidepressants. Moreover, we will be using
the design/participatory action research we have used to
design user- and context-sensitive decision aids. Further-
more, the design of the study reflects years of lessons
learned while conducting practice-based trials in primary
care settings aimed at minimizing research footprint in
practices (see list below of key elements we find contribute
to the successful implementation of practice-based
decision aid trials).
Key elements of conducting successful practice-based
trials of decision aids
 Recruiting practices, rather than clinicians alone, so
that every member of the staff is engaged in the
conduct of the trial.
 Ensuring that targeted practices have both a clinical
champion and sufficient eligible patients to meet
recruitment goals.
 Ensuring the recruitment of clinicians with sufficient
eligible patients within each practice.
 Involving practices, clinicians, patients and staff in
the development of the intervention (decision aid),
so that it meets their needs.
 Engaging clinicians and patients as collaborators of
the study, rather than as ‘subjects’ of the study.
 Favoring an opt-out approach while recruiting
clinicians.
 Minimizing research footprint on the practice (using
study coordinators to identify and recruit patients,
operating mindful of the practice workflow).
 Minimizing burden of the trial procedures on
patients and clinicians with brief and few surveys,
making paper and electronic surveys available, and
using already scheduled meetings by the practice to
provide study updates.
Finally, this proposal will help to highlight ways by which
we can better engage patients with depression in their care.
The evidence on shared decision making among patients
receiving mental healthcare is still emerging [38-40].
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tal healthcare needs to participate in healthcare decisions
persists, and may be compounded by prejudices and mis-
understandings regarding the capacity of these patients
[39]. However, patients with mental healthcare needs have
demonstrated competence in healthcare decision making
[41], and the Institute of Medicine gives a strong recom-
mendation for using decision support with all patients with
mental healthcare needs regardless of the condition’s sever-
ity [42]. Additionally, patients with depression may experi-
ence additional benefits from the shared decision making
process as they become engaged in their care, and find that
their preferences and opinions are valued [39,43,44].
Upon completion of the proposed research we will have
developed and evaluated the efficacy of the decision aid
Depression Medication Choice as a novel translational
tool for CER in depression treatment, and refined the
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